Edition:
United Kingdom

Ablynx NV (ABLX.OQ)

ABLX.OQ on NASDAQ Stock Exchange Global Select Market

23.93USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$23.93
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
--
52-wk High
$24.24
52-wk Low
$17.75

Select another date:

Thu, Nov 16 2017

BRIEF-Ablynx 9-month revenues decrease to 44.7 million euros ​

* 9 MONTH REVENUES OF EUR 44.7 MILLION (2016: EUR 68.9 MILLION)​

BRIEF-Ablynx announces full exercise of underwriters' option to purchase additional shares

* ABLYNX ANNOUNCES FULL EXERCISE OF UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES AND END OF STABILIZATION PERIOD

BRIEF-Ablynx prices $200 mln IPO in the United States

* Ablynx prices $200 million initial public offering in the United States

BRIEF-Ablynx NV now sees IPO of up to 9.5 mln ordinary shares

* Ablynx NV now sees IPO of up to 9.5 million ordinary shares including 8.1 million ordinary shares in form of American Depositary Shares - sec filing

BRIEF-Ablynx NV offers 9.2 million of its ordinary shares in global offering

* Ablynx NV sees offering of 9.2 million of its ordinary shares in a global offering - SEC filing

BRIEF-Ablynx to offer and sell about $175 million of its ordinary shares

* ‍INTENDS TO OFFER AND SELL ABOUT $175 MILLION OF ITS ORDINARY SHARES IN A GLOBAL OFFERING​

BRIEF-Ablynx establishes subsidiary in USA

* ABLYNX ESTABLISHES SUBSIDIARY IN THE USA AND APPOINTS A GENERAL MANAGER Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Ablynx NV files for U.S. IPO of up to $150 mln

* Ablynx NV files for U.S. IPO of up to $150.0 million ‍- SEC filing‍​

Belgian biotech Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion (£825 million).

Belgian biotech Ablynx scores big hit with blood disease drug

Belgian biotech company Ablynx reported resoundingly positive data for an experimental drug against a rare blood disorder on Monday, sending its market value above $1.1 billion.

Select another date: